Emerging Therapies for Hereditary Ataxia—Second Edition

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: closed (25 June 2025) | Viewed by 1435

Special Issue Editors


E-Mail Website
Guest Editor
Department of Anatomy, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
Interests: neuroanatomy of cerebellar ataxia; modulators of oxidative stress; functional food
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
Interests: neurogenetics; neurodegeneration; neurodevelopment
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy
Interests: neurodegenerative diseases; neurodevelopment; oxidative stress
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We invite the submission of original research and review articles for a Special Issue titled “Emerging Therapies for Hereditary Ataxia—Second Edition”. Hereditary ataxia (HA) represents a group of genetically heterogeneous neurodegenerative diseases. It can be classified by the pattern of inheritance: autosomal dominant, autosomal recessive, or X-linked ataxia. Mitochondrial dysfunction and oxidative damage have been increasingly implicated in the pathogenesis of HA. With no cure and a reduced lifespan, HA causes motor incoordination and progressive functional disabilities in young and middle-aged populations. The lack of effective therapeutic options remains a major gap in the field. Therapy aimed at boosting antioxidant defenses is efficient in the treatment of HA. The combined use of a mitochondrial antioxidant and an iron-binding chelator is rapidly emerging as a powerful therapeutic strategy for a wide range of HAs. Stem cell transplantation may represent a new avenue for clinical research in HA. Additionally, complementary and alternative medicines could play a key role in regulating cellular metabolic processes including inflammatory signaling, mitochondrial function. and lipid metabolism, therefore facilitating the process of drug development and discovery for HA. We welcome cellular models of pathology and in vivo studies that provide valuable information for all stages of biomedical research, as well as research involving human subjects in compliance with the Declaration of Helsinki.

Potential topics include, but are not limited to, the following:

  • Disease-modifying management of hereditary ataxia;
  • Stem cell transplantation for hereditary ataxia;
  • Dysregulation of iron metabolism and mitochondrial dysfunction;
  • Role of oxidative stress in hereditary ataxia;
  • Future perspectives for complementary and alternative medicines.

Dr. Kah-Hui Wong
Dr. Patrícia Maciel
Dr. Piergiorgio La Rosa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hereditary ataxia
  • movement disorder
  • emerging neurotherapeutics
  • complementary and alternative medicines
  • secondary metabolites
  • neuroprotection
  • mitigation of oxidative stress
  • mitochondria-targeted antioxidants

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 850 KB  
Review
Oxidative Stress and Antioxidant Therapies in Friedreich’s Ataxia
by Félix Javier Jiménez-Jiménez, Hortensia Alonso-Navarro, Elena García-Martín, Alba Cárcamo-Fonfría, Miguel Angel Martín-Gómez and José A. G. Agúndez
Cells 2025, 14(18), 1406; https://doi.org/10.3390/cells14181406 - 9 Sep 2025
Viewed by 834
Abstract
The pathogenesis of Friedreich’s ataxia (FRDA) remains poorly understood. The most important event is the deficiency of frataxin, a protein related to iron metabolism and, therefore, involved in oxidative stress. Studies on oxidative stress markers and gene expression in FRDA patients have yielded [...] Read more.
The pathogenesis of Friedreich’s ataxia (FRDA) remains poorly understood. The most important event is the deficiency of frataxin, a protein related to iron metabolism and, therefore, involved in oxidative stress. Studies on oxidative stress markers and gene expression in FRDA patients have yielded inconclusive results. This is largely due to the limited number of studies, small sample sizes, and methodological differences. A notable finding is the decreased activity of mitochondrial respiratory chain complexes I, II, and III, as well as aconitase, in endomyocardial tissue. In contrast, numerous studies in experimental models of FRDA (characterized by frataxin deficiency) have shown evidence of the involvement of oxidative stress in cellular degeneration. These findings include increased iron concentration, mitochondrial dysfunction (with reduced respiratory chain complex activity and membrane potential), and decreased aconitase activity. Additionally, there is the induction of antioxidant enzymes, reduced glutathione levels, elevated markers of lipoperoxidation, and DNA and carbonyl protein oxidation. The expression of NRF2 is decreased, along with the downregulation of PGC-1α. Therefore, it is plausible that antioxidant treatment may help improve symptoms and slow the progression of FRDA. Among the antioxidant treatments tested in FRDA patients, only omaveloxolone and, to a lesser extent, idebenone (particularly for cardiac hypertrophy) have shown some efficacy. However, many antioxidant drugs have shown the ability to reduce oxidative stress in experimental models of FRDA. Therefore, these drugs may be useful in treating FRDA and are likely candidates for future clinical trials. Future studies investigating oxidative stress and antioxidant therapies in FRDA should adopt a prospective, multicenter, long-term, double-blind design. Full article
(This article belongs to the Special Issue Emerging Therapies for Hereditary Ataxia—Second Edition)
Show Figures

Figure 1

Back to TopTop